buyModerate cluster of 2
Rohan Palekar bought $39k of ETNB
Chief Executive Officer at 89bio, Inc.. 5,000 shares at an average of $7.89, traded Dec 6, 2024, filed Dec 10, 2024.
Conviction score
44Value
$39k
5,000 shares
Holdings after
471,236
+1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +6Trade size$39k at market
- 0Relative to holdingsHoldings up 1.1%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-24-134750, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 6, 2024 | POpen-market purchase Common Stock | +5,000 | $7.89 | $39k | 471,236 | Dec 10, 2024 |
Related signals
Other insiders at 89bio, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 5Weak | 89bio, Inc. | Quoc Le-Nguyen See Remarks | $115k 10,461 shares | -3% | |
| 4Weak | 89bio, Inc. | Quoc Le-Nguyen See Remarks | $91k 15,329 shares | -4% | |
| 54Moderate | 89bio, Inc. | Ra Capital Management, L.p. director, owner | $50M 5,714,285 shares | +41% | |
| 48Moderate | 89bio, Inc. | Charles McWherter director | $100k 15,000 shares | +150% | |
| 3Weak | 89bio, Inc. | Quoc Le-Nguyen See Remarks | $71k 10,963 shares | -4% | |
| 40Moderate | 89bio, Inc. | Charles McWherter director | $80k 10,000 shares | - | |
| 42Moderate | 89bio, Inc. | Rohan Palekar Chief Executive Officer | $84k 10,000 shares | +2% | |
| 13Weak | 89bio, Inc. | Quoc Le-Nguyen See Remarks | $227k 27,955 shares | -13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.